Myasthenia Gravis Market Research Report – Global Forecast till 2030

Myasthenia Gravis Market Size, Growth and Insights By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis and Others), (Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations) and By Region-Global Forecast Till 2030

ID: MRFR/HC/5800-CR | January 2019 | Region: Global | 175 Pages         

Myasthenia Gravis Market Speak to Analyst Request a Free Sample

Myasthenia gravis treatment market

The global myasthenia gravis treatment market is estimated to reach USD 1.18 billion and at a CAGR of 7.8% over the forecast period of 2022-2030

By Type Ocular Myasthenia Gravis Congenital Myasthenia Gravis Generalized Myasthenia Gravis Transient Myasthenia Gravis
By End User Hospitals and Clinics Diagnostic Centers and Academic and Research Organizations
Key Players
Companies Profiled   GE Healthcare   Novartis AG   Boston Scientific Corporation   Grifols S.A.   Koninklijke Philips N.V.   Alexion PharmaceuticalsInc.
Market Driving Forces   Rising Prevelance of Myasthenia gravis
Request a Free Sample

Myasthenia Gravis Market Overview:

In addition, the global myasthenia gravis market Market will have a value of USD 1.18 billion by 2030 to grow at a CAGR of 10.10% with a significant value during the projected quarters of 2020-2030.

Due to rapid urbanization and hectic schedules, there is a rise in fast food consumption among individuals. This, along with sedentary lifestyles and the increasing number of patients with medical conditions like multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders, is one of the primary factors propelling the market's growth. Additionally, rising awareness about early diagnosis and the increasing preferences for personalized medicines contribute to market growth. Moreover, through various routes of administration, immunoglobulin helps the body fight multiple infectious diseases.

Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and difficulty walking. Although a rare disease, the prevalence of the disease has increased over the past few decades, as per National Organization for Rare Disorders. As a result, the research and development in understanding the disease and finding a cure have also increased.

Myasthenia Gravis Market Overview

This MRFR perspective presents a holistic outlook on the global myasthenia gravis market. It also includes a revenue forecast till 2023 along with a three-year (2015-2018) historical analysis. Market dynamics such as drivers, restraints and opportunities have been thoroughly discussed in the research document. Also, market assessment based on various types of myasthenia gravis (ocular myasthenia gravis, congenital myasthenia gravis, generalized myasthenia gravis, transient myasthenia gravis and others) is also available in the report.

Myasthenia Gravis Market Report Coverage

Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market

Companies Covered

GE Healthcare, Alexion Pharmaceuticals, Inc, Novartis AG, Pfizer Inc., Boston Scientific Corporation, CSL Behring, Medtronic Plc., Baxter, Grifols S.A., Shire, Koninklijke Philips N.V., and Valeant Pharmaceuticals International, Inc.

Research Methodology

MRFR is committed to deliver a highly accurate market outlook, deep-diving into the crux. This is done by following a systematic and fail-safe research structure. It ensures market sizing and evaluation is conducted with an unbiased viewpoint and presentation of error-free perspective. A combination of primary and secondary research input allows accountability of market findings. For this, a wide variety of research material is amassed, which includes surveys, bites from c-level executives, expert opinion, white paper, SEC filing, paid database services etc. Emphasis is placed on delivering actional market insights though extensive data assessment. In addition, verification of research findings involves undertaking of top-down and bottom-up approaches.Recent Development

The prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population, translating to 36,000 to 60,000 cases in the United States. However, the report states that myasthenia gravis may be underdiagnosed in many cases and has a higher prevalence. The report also suggests that women are more often affected than men. At the onset, the most common age is in the 20s and 30s in women and the 60s and 70s in men.

Most of the myasthenia gravis therapeutics are manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness, which has also helped the market grow.

By Type

  • Ocular myasthenia gravis

  • Congenital myasthenia gravis

  • Generalized myasthenia gravis

  • Transient myasthenia gravis

  • Others

By Diagnosis and Treatment

  • Diagnosis

    • Lab-based test

    • Electrodiagnostic testing & imaging

  • Treatment

    • Cholinesterase inhibitors

    • Immunosuppressive drugs

    • Plasmapheresis and intravenous immunoglobulin

    • Thymectomy

End User

  • Hospitals and Clinics

  • Diagnostic Centers

  • Academic and Research organizations

By Region

  • North America

  • Europe

  • Asia Pacific

  • The Middle East & Africa (MEA)

  • Latin America

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Myasthenia Gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body.

Myasthenia Gravis Market is expected to exhibit a strong 10.10% CAGR over the forecast period from 2020 to 2030.

Increasing prevalence of neuromuscular disorders and the growing awareness about the disease are the major drivers for the Myasthenia Gravis Market.

Americas accounted for the largest share in the market in 2016.

Leading players in the Myasthenia Gravis Market include Valeant, Piramal Healthcare, and Biogen Inc., among others.